Patients with high-risk prostate cancer initiating long-term hormone therapy will likely benefit from two new treatments with comparable efficacy and safety profiles, according to the results of a trial presented at the 2017 ESMO conference (September 8-12, 2017; Madrid, Spain).
NEW YORK (Reuters Health) – Androgen-deprivation therapy (ADT) is associated with an increased risk of heart failure (HF) in men with localized prostate cancer who have no pre-existing cardiovascular disease (CVD), according to a prospective study using electronic health records.
NEW YORK (Reuters Health) - In patients with prostate adenocarcinoma, postdiagnosis statin use was associated with reduced mortality both from prostate cancer (PC) and from all causes, according to a nationwide registry study from Denmark.
Older age is associated with a lesser chance of receiving definitive therapy and a higher chance of receiving primary androgen deprivation therapy in patients with intermediate-risk or high-risk prostate cancer, according to research published in Cancer (online August 22, 2017; doi:10.1002/cncr.30948).
Progression-free survival (PFS) is not improved in patients with metastatic castration-resistant prostate cancer (mCRPC) when enzalutamide is added to abiraterone acetate with prednisone, compared with abiraterone with prednisone alone, according to findings from a new trial.
Increase in metastatic prostate cancer in older men has a definitive correlation with changes in prostate cancer screening guidelines recommending against prostate-specific antigen (PSA) testing, according to research published in JAMA Oncology.
Using testosterone-lowering drugs to treat prostate cancer may make men twice as likely to develop dementia within five years as patients whose testosterone levels were not tampered with, according to a retrospective study.